Humana price target lowered to $541 from $610 at Wells Fargo

Wells Fargo analyst Stephen Baxter lowered the firm’s price target on Humana to $541 from $610 and keeps an Overweight rating on the shares. The updated price target reflects commentary on Medicare utilization, but Wells Fargo thinks the company can pull NT levers to sustain earnings trajectories and remain among the best positioned over the long run, the analyst tells investors in a research note.